Corporate Presentation, Nov 2016

ASX: NOX

Board

Graham Kelly *PhD*
CEO & Managing Director

- Head of research team at University of Sydney that discovered idronoxil in 1992
- Founded (CEO) Novogen Ltd (ASX 1994; NASDAQ 1998). Executive Director 1994-2006)
- Chairman of Marshall Edwards Inc (AIM 2001; NASDAQ 2003)
- CEO/Executive Chairman Novogen Ltd 2012-2015
- Founded Noxopharm October 2015

Dr Ian Dixon *PhD, MBA*
Non-Executive Director

- Over 20 years' experience in the biotechnology and medical device industries and was founder/co-founder of numerous successful technology companies, including Cynata Ltd, Genscreen Pty Ltd and August Therapeutics.
- Previously a non-executive Director of Cell Therapies Pty Ltd, and Director of the Product Group at Invetech, now part of Danaher Corporation (NYSE: DHR).
- Led early development of the anti-tropomyosin drug technology that his company licensed to Novogen Ltd.

Peter Marks
Non-Executive Chairman

- 30+ years experience in corporate finance, specializing in capital raisings (for listed and unlisted companies), underwriting, IPOs and venture capital transactions.
- Participated in over $2B in public and private capital raised.
- Executive and Non-Executive Director of a number of listed entities on the ASX and AIM

Phillip Hains *MBA*
Company Secretary

- Phillip holds a Masters of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants.

  As a chartered accountant, Phillip operates his own specialist public practice, The CFO Solution, providing back-office support, financial reporting and compliance systems for public companies.

  Phillip has over 20 years' experience in providing businesses with accounting, administration, compliance and general management services.

key metrics

Listed:	**9 Aug 2016**
Raised:	**$6m**
Current:	**$4.8m**
Projected runway:	**mid-2018**



NOXOPHARM

securities

1.	Listed Shares (NOX)	33,560,000	758
2.	Escrowed Shares Jan 2017	464,750	1
3.	Escrowed Shares April 2017	4,261,214	1
4.	Escrowed Shares Sept 2018	36,885,465	7
5.	Options 1*	357,500	1
6.	Options 2**	3,277,858	21
7.	Options 3***	18,950,358	7
8.	Performance Shares****	10,000,000	4

OPTIONS

1. * @ $0.30: Escrowed until 8/1/17: Expire 28/2/21
2. ** @ $0.30: Escrowed until 1/4/17: Expire 28/2/21
3. *** @ $0.30: Escrowed until 1/4/17: Expire 28/2/21
4. **** Escrowed until 9 August 2018. Market cap of $50m

Top 5 Shareholders (at 12 Nov 2016)	
GE & PR Kelly Family Trust	32.1%
DRH Superannuation P/L	7.3%
Anglo Menda Pty Ltd	6.4%
HSBC Custody Nominees Ltd	2.5%
Aquagolf P/L	1.9%

Fully diluted:

Shares on issue: **100,757,145**

G & P Kelly: 42.775M (42.45%)

NOXOPHARM

Our objective

To bring to market the first drug that sensitises cancer cells to cancer therapies

to improve the survival outcomes of standard **chemotherapy** and **radiotherapy**

and allow effective dosages of standard chemotherapy and radiotherapy **to be lowered to non-toxic levels**

and thereby provide treatment options for the elderly and frail and the significant population of patients who elect **not to undergo toxic therapies**

NOXOPHARM

in a nutshell……..

In 1971, cancer researchers dreamt of turning cancer into a manageable, non-lethal, chronic disease

45 years later that dream remains elusive for most types of cancer

In 1971, chemotherapy and radiotherapy were the standard frontline therapies

45 years later, chemotherapy and radiotherapy remain our best treatment options

NOXOPHARM

in a nutshell……..

The dream remains elusive because chemotherapy and radiotherapy are not being used to their full powers ….

because **damage to healthy cells dictates the highest dose of chemo and radiotherapy that can be used, and that dose is not enough to kill all cancer cells**

If a way could be found to increase the sensitivity of cancer cells to current doses of chemotherapy and radiotherapy so that ALL cancer cells were killed ….

….. then the 1971 dream should be achievable.

NOXOPHARM

Noxopharm believes it has the answer……..

IDRONOXIL: **sensitises cancer cells (and only cancer cells) to standard chemotherapy and radiotherapy**

IDRONOXIL : **dramatic level of sensitisation >2000x**

NOX66: **delivering IDRONOXIL in a form designed to maintain its activity in the body**

NOX66: **Noxopharm seeks to make NOX66 standard of care for all patients undergoing chemotherapy and radiotherapy**

NOXOPHARM

45 years later….

1971:
President Richard Nixon signs National Cancer Act
Declares **“War on cancer”**

the war continues

2016:
Vice-President Joe Biden
Announces **“Cancer moonshot”**

NOXOPHARM

After 45 years of *'the war on cancer'…….*
10-year survival rates remain poor for many cancers



Source; Cancer Research UK

Little or no progress made in survival outcome for cancers of:

- Pancreas
- Lung
- Brain
- Head and neck
- Oesophagus
- Stomach
- Cervix
- Bladder

BUT….even where progress has been made, most cancers eventually recur and ultimately become resistant to chemotherapy and radiotherapy

Frontline cancer therapies work by damaging DNA



Radiotherapy

Chemotherapy

Aim is to damage DNA beyond repair

cell dies

NOXOPHARM

The problem

MAXIMUM TOLERABLE DOSE
Highest dose of chemotherapy or radiotherapy that can be delivered is determined by the highest dose that can be tolerated by the patient.

NOXOPHARM

The problem

The Maximum Tolerated Dose leaves many cancer cells alive



NOXOPHARM

The solution



To sensitise cancer cells
(*and only cancer cells*)
to DNA-damaging effects of chemotherapy and radiotherapy so that ALL cancer cells are killed

NOXOPHARM

The answer



Idronoxil

Sensitises all forms of cancer cells
(*but not healthy cells*)

by > 2,000x

to all standard cytotoxic
chemotherapy drugs

and radiotherapy

NOXOPHARM

Idronoxil history



Discovered in 1992

Basis of formation of Novogen Ltd (ASX:1994).

Named **phenoxodiol**.

Potent ability to sensitise chemotherapy confirmed

Enters clinic in 1999

Novogen market cap = $900 million

Evidence of anti-cancer benefits observed in Phase II studies alone and in combination

Phase III study (phenoxodiol + carboplatin) in late-stage ovarian cancer abandoned in 2009

NOXOPHARM

Idronoxil failed because of Phase 2 metabolism… .or how the body deals with water-insoluble

Aspirin
Paracetamol
Codeine
Steroids

D



Drug active

Body attaches sugar

D + S

Drug circulates combined to sugar

D S

Drug now inactive

Combination enters cell

D S

Sugar-removing enzymes

D S

Sugar-removing enzymes

Drug freed from the sugar now active

NOXOPHARM

Idronoxil and Phase 2 metabolism



NOXOPHARM

NOX66





Body unable to attach sugar



S

Idronoxil remains in ACTIVE form

Proprietary formulation





Interacts with target on outside of cancer cell

NOXOPHARM

Clinical Program



Cytotoxic chemotherapy

Radiotherapy

NOXOPHARM

Clinical studies

Patients with late-stage cancers that have failed to respond to **standard therapies** and have **no remaining standard treatment options**

Q1. Can NOX66 result in a significant anti-cancer response where none is expected?

Q2. Can NOX66 allow dosages of chemotherapy and radiotherapy to be lowered to levels that will be well tolerated?

NOXOPHARM

Clinical strategy

To run a broad clinical trial program designed to identify:

1. The best treatment combination
   - chemotherapy?
   - radiotherapy?
2. The best purpose of use
   - Make standard dose work better?
   - Allow use of lower dose?
3. Optimal cancer type
   - Prostate, lung, other ??

NOXOPHARM

AIM:
- to have proof-of-concept by end-2017
- decision on indication for registration studies by end of 1Q-2018



5x R&D programs

A. Customized NOX66 formulations for specific cancer types

B. Second- and third-generation radio-sensitising drugs

C. Use of NOX66 delivery technology for non-oncology purposes

NOXOPHARM

Milestones achieved

A. Foundation staff appointed:
- **In-house clinical affairs team**
- **Scientific team**
- **Manufacturing/chemistry capacity**
- **IR function**

B. Appointment of key medical advisors

C. Clinical trial batch of NOX66 manufactured

D. Sites and investigators for 5 clinical trials recruited

E. 5x R&D projects identified and activated

Guidance on key milestones for next 12 months

A. Opening of 5 clinical studies (Dec 2017 – June 2018)

B. Proof-of-concept data to be reported on from at least 3 clinical studies

C. Progress in 5x R&D programs; new IP

NOXOPHARM

IP position

Idronoxil	Structure not patentable. First described by G. Kelly in 1994.
Patent lodgement	Family of provisional patents lodged. Claims revolve around innovative formulation designed to block Phase 2 metabolism and conserve bio-activity
2nd and 3rd generation products	R&D programs initiated with intention of delivering a family of therapeutics with specific abilities to cancel resistance mechanisms

NOXOPHARM

Key Messages

- Resistance to chemotherapy/radiotherapy remains the most pressing and largest problem facing cancer patients
- No drug has come to market that successfully treats this problem
- WE EXPECT TO KNOW WITHIN 12 MONTHS OF THE SUCCESS OF OUR MISSION
- AN EXTENSIVE R&D PROGRAM IS IN PLACE AS A DE-RISKING STRATEGY
- A SUCCESSFUL OUTCOME IS A MAJOR SHARE OF THE $100 BILLION ONCOLOGY DRUG MARKET

✓ Lean, focused operation

✓ key inflection points anticipated within next 18 months

✓ Potential for NOX66 to become standard of care

Disclaimer

- *This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscribe for or purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.*
- *This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.*
- *This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.*
- *Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.*
- *Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.*

Contact

Dr Graham Kelly
Chief Executive Officer

graham.kelly@noxopharm.com